Edwards Lifesciences (EW)
(Delayed Data from NYSE)
$67.23 USD
-2.13 (-3.07%)
Updated Sep 17, 2024 04:00 PM ET
Pre-Market: $66.01 -1.22 (-1.81%) 9:26 AM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$67.23 USD
-2.13 (-3.07%)
Updated Sep 17, 2024 04:00 PM ET
Pre-Market: $66.01 -1.22 (-1.81%) 9:26 AM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
Zacks News
Earnings Preview: Edwards Lifesciences (EW) Q3 Earnings Expected to Decline
by Zacks Equity Research
Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for Edwards Lifesciences' (EW) Q3 Earnings?
by Zacks Equity Research
Robust customer adoption of the TruWave disposable pressure monitoring devices and the INSPIRIS RESILIA aortic valve is likely to have driven Edwards Lifesciences' (EW) Q3 revenues.
Edwards Lifesciences (EW) Up 1.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
TMO vs. EW: Which Stock Is the Better Value Option?
by Zacks Equity Research
TMO vs. EW: Which Stock Is the Better Value Option?
Edwards Lifesciences (EW) Beats on Q2 Earnings, Ups EPS View
by Zacks Equity Research
Despite coronavirus-hit sales, Edwards Lifesciences (EW) witnessed steady improvement in TAVR procedure volumes in Q2. Regulatory approvals look encouraging.
Bear of the Day: Penumbra (PEN)
by Kevin Cook
Growth stalls for an innovator in blood clot removal and the deadly shadow of stroke with catheter-based aspiration technologies
Edwards Lifesciences (EW) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Edwards Lifesciences (EW) delivered earnings and revenue surprises of 126.67% and 18.15%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for Edwards Lifesciences (EW)
by Zacks Equity Research
Edwards Lifesciences (EW) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Analysts Estimate Edwards Lifesciences (EW) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for Edwards Lifesciences (EW) in Q2 Earnings?
by Zacks Equity Research
Robust customer adoption of the TruWave disposable pressure monitoring devices and INSPIRIS RESILIA aortic valve are likely to have driven Edwards Lifesciences' (EW) Q2 revenues.
Medical Instruments Outlook Dull Amid Coronavirus Crisis
by Urmimala Biswas
Many sub domains within the medical instrument space are bearing the brunt of the coronavirus-led prolonged stay-at-home orders.
Here's Why You Should Hold on to Edwards Lifesciences for Now
by Zacks Equity Research
Investors continue to be upbeat about Edwards Lifesciences (EW) owing to its strong segmental growth and robust product demand.
3 Cheap MedTech Stocks Set to Gain Once Coronavirus Crisis Ebbs
by Sriparna Ghosal
Once the pandemic-led crisis eases, these MedTech stocks will likely flourish on the back of number of positive developments.
Edwards Lifesciences' SAPIEN 3 THV Cleared for Use in China
by Zacks Equity Research
Edwards Lifesciences' (EW) SAPIEN 3 THV to be used an alternative to open-heart surgery for high and extreme-risk AS patients post approval in China.
Here's Why You Should Hold on to Edwards Lifesciences for Now
by Zacks Equity Research
Investors continue to be optimistic about Edwards Lifesciences (EW) on robust demand for products and a promising surgical structural heart business.
Edwards Lifesciences (EW) Down 1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Zacks Analyst Blog Highlights: Cisco, Abbott Laboratories, NextEra Energy, Gilead Sciences and Edwards Lifesciences
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Cisco, Abbott Laboratories, NextEra Energy, Gilead Sciences and Edwards Lifesciences
Top Stock Research Reports for Cisco, Abbott, NextEra & Others
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Cisco (CSCO), Abbott Laboratories (ABT) and NextEra Energy (NEE).
The Zacks Analyst Blog Highlights: Intel and Edwards Lifesciences
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Intel and Edwards Lifesciences
Edwards Lifesciences (EW) Beats on Q1 Earnings, Cuts '20 View
by Zacks Equity Research
Amid the coronavirus impact on sales, Edwards Lifesciences (EW) witnesses growth in TAVR procedures led by strong therapy adoption across all geographies, particularly in the United States.
Intel, Edwards Lifesciences Top Q1 Earnings Estimates
by Mark Vickery
The chipmaker giant and the MedTech company both outperformed expectations in their Q1 earnings reports.
Edwards Lifesciences (EW) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Edwards Lifesciences (EW) delivered earnings and revenue surprises of 17.05% and 7.64%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Can TAVR's SAPIEN 3 Aid Edwards Lifesciences (EW) Q1 Earnings?
by Zacks Equity Research
Robust customer adoption of the HemoSphere all-in-one monitoring platform and TAVR treatments is likely to have driven Edwards Lifesciences' (EW) Q1 revenues.
Edwards Lifesciences (EW) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Edwards Lifesciences (EW) closed the most recent trading day at $217.52, moving +1.34% from the previous trading session.
Edwards Lifesciences (EW) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.